The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Prostate cancer has become a significant health concern among men, being the second leading cause of death in the United States. While the survival rate in men remains high, those who have advanced, ...

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Prostate and skin cancers are among the most common cancers affecting men. In Advanced Prostate Cancer, lifelong treatment modalities are making a difference, challenges remain for patients with high ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...